Skip Nav Destination
Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A
An international registry of survivors with Hb Bart's hydrops fetalis syndrome
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma
Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide
Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy
Issue Archive
March 9 2017
In this Issue
Table of Contents
INSIDE BLOOD COMMENTARIES
PLENARY PAPER
THROMBOSIS AND HEMOSTASIS
Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A
Clinical Trials & Observations
Antonino Cannavò,on behalf of the SIPPET study group,Carla Valsecchi,on behalf of the SIPPET study group,Isabella Garagiola,on behalf of the SIPPET study group,Roberta Palla,on behalf of the SIPPET study group,Pier Mannuccio Mannucci,on behalf of the SIPPET study group,Frits R. Rosendaal,on behalf of the SIPPET study group,Flora Peyvandi,on behalf of the SIPPET study group
PERSPECTIVE
An international registry of survivors with Hb Bart's hydrops fetalis syndrome
Clinical Trials & Observations
Duantida Songdej,in collaboration with the BHFS International Consortium,Christian Babbs,in collaboration with the BHFS International Consortium,Douglas R. Higgs,in collaboration with the BHFS International Consortium
REVIEW ARTICLE
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab
Clinical Trials & Observations
Yasmin Abaza,Hagop Kantarjian,Guillermo Garcia-Manero,Elihu Estey,Gautam Borthakur,Elias Jabbour,Stefan Faderl,Susan O’Brien,William Wierda,Sherry Pierce,Mark Brandt,Deborah McCue,Rajyalakshmi Luthra,Keyur Patel,Steven Kornblau,Tapan Kadia,Naval Daver,Courtney DiNardo,Nitin Jain,Srdan Verstovsek,Alessandra Ferrajoli,Michael Andreeff,Marina Konopleva,Zeev Estrov,Maria Foudray,David McCue,Jorge Cortes,Farhad Ravandi
GENE THERAPY
TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1
Lorenz Jahn,Pleun Hombrink,Renate S. Hagedoorn,Michel G. D. Kester,Dirk M. van der Steen,Tania Rodriguez,Tsvetelina Pentcheva-Hoang,Arnoud H. de Ru,Marjolein P. Schoonakker,Miranda H. Meeuwsen,Marieke Griffioen,Peter A. van Veelen,J. H. Frederik Falkenburg,Mirjam H. M. Heemskerk
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma
Clinical Trials & Observations
Teru Hideshima,Francesca Cottini,Yoshihisa Nozawa,Hyuk-Soo Seo,Hiroto Ohguchi,Mehmet K. Samur,Diana Cirstea,Naoya Mimura,Yoshikazu Iwasawa,Paul G. Richardson,Nikhil C. Munshi,Dharminder Chauhan,Walter Massefski,Teruhiro Utsugi,Sirano Dhe-Paganon,Kenneth C. Anderson
MYELOID NEOPLASIA
Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment
Manar S. Shafat,Thomas Oellerich,Sebastian Mohr,Stephen D. Robinson,Dylan R. Edwards,Christopher R. Marlein,Rachel E. Piddock,Matthew Fenech,Lyubov Zaitseva,Amina Abdul-Aziz,Jeremy Turner,Johnathan A. Watkins,Matthew Lawes,Kristian M. Bowles,Stuart A. Rushworth
Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia
Clinical Trials & Observations
Tilmann Bochtler,for the Study Alliance Leukemia Investigators,Martin Granzow,for the Study Alliance Leukemia Investigators,Friedrich Stölzel,for the Study Alliance Leukemia Investigators,Christina Kunz,for the Study Alliance Leukemia Investigators,Brigitte Mohr,for the Study Alliance Leukemia Investigators,Mutlu Kartal-Kaess,for the Study Alliance Leukemia Investigators,Katrin Hinderhofer,for the Study Alliance Leukemia Investigators,Christoph E. Heilig,for the Study Alliance Leukemia Investigators,Michael Kramer,for the Study Alliance Leukemia Investigators,Christian Thiede,for the Study Alliance Leukemia Investigators,Volker Endris,for the Study Alliance Leukemia Investigators,Martina Kirchner,for the Study Alliance Leukemia Investigators,Albrecht Stenzinger,for the Study Alliance Leukemia Investigators,Axel Benner,for the Study Alliance Leukemia Investigators,Martin Bornhäuser,for the Study Alliance Leukemia Investigators,Gerhard Ehninger,for the Study Alliance Leukemia Investigators,Anthony D. Ho,for the Study Alliance Leukemia Investigators,Anna Jauch,for the Study Alliance Leukemia Investigators,Alwin Krämer,for the Study Alliance Leukemia Investigators
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
Mature CD10+ and immature CD10− neutrophils present in G-CSF–treated donors display opposite effects on T cells
Olivia Marini,Sara Costa,Dalila Bevilacqua,Federica Calzetti,Nicola Tamassia,Cecilia Spina,Donata De Sabata,Elisa Tinazzi,Claudio Lunardi,Maria T. Scupoli,Chiara Cavallini,Elisa Zoratti,Ilaria Tinazzi,Antonio Marchetta,Aurora Vassanelli,Maurizio Cantini,Giorgio Gandini,Andrea Ruzzenente,Alfredo Guglielmi,Francesco Missale,William Vermi,Cristina Tecchio,Marco A. Cassatella,Patrizia Scapini
THROMBOSIS AND HEMOSTASIS
Alteration of blood clotting and lung damage by protamine are avoided using the heparin and polyphosphate inhibitor UHRA
Manu Thomas Kalathottukaren,Libin Abraham,Piyushkumar R. Kapopara,Benjamin F. L. Lai,Rajesh A. Shenoi,Federico I. Rosell,Edward M. Conway,Edward L. G. Pryzdial,James H. Morrissey,Charles A. Haynes,Jayachandran N. Kizhakkedathu
TRANSPLANTATION
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma
Clinical Trials & Observations
Reid W. Merryman,Haesook T. Kim,Pier Luigi Zinzani,Carmelo Carlo-Stella,Stephen M. Ansell,Miguel-Angel Perales,Abraham Avigdor,Ahmad S. Halwani,Roch Houot,Tony Marchand,Nathalie Dhedin,Willy Lescaut,Anne Thiebaut-Bertrand,Sylvie François,Aspasia Stamatoullas-Bastard,Pierre-Simon Rohrlich,Hélène Labussière Wallet,Luca Castagna,Armando Santoro,Veronika Bachanova,Scott C. Bresler,Amitabh Srivastava,Harim Kim,Emily Pesek,Marie Chammas,Carol Reynolds,Vincent T. Ho,Joseph H. Antin,Jerome Ritz,Robert J. Soiffer,Philippe Armand
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide
Brief Report
Christopher G. Kanakry,Javier Bolaños-Meade,Yvette L. Kasamon,Marianna Zahurak,Nadira Durakovic,Terry Furlong,Marco Mielcarek,Marta Medeot,Ivana Gojo,B. Douglas Smith,Jennifer A. Kanakry,Ivan M. Borrello,Robert A. Brodsky,Douglas E. Gladstone,Carol Ann Huff,William H. Matsui,Lode J. Swinnen,Kenneth R. Cooke,Richard F. Ambinder,Ephraim J. Fuchs,Marcos J. de Lima,Borje S. Andersson,Ravi Varadhan,Paul V. O’Donnell,Richard J. Jones,Leo Luznik
LETTERS TO BLOOD
Sorting zebrafish thrombocyte lineage cells with a Cd41 monoclonal antibody enriches hematopoietic stem cell activity
John M. Gansner,Alexander D. Leung,Michael Superdock,Megan C. Blair,Michelle B. Ammerman,Ellen M. Durand,Bruce Barut,Robert I. Handin,David L. Stachura,Chafen Lu,Timothy A. Springer,Leonard I. Zon
Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy
Clinical Trials & Observations
Eric J. Duncavage,Geoffrey L. Uy,Allegra A. Petti,Christopher A. Miller,Yi-Shan Lee,Bevan Tandon,Feng Gao,Catrina C. Fronick,Michelle O’Laughlin,Robert S. Fulton,Richard K. Wilson,Meagan A. Jacoby,Amanda F. Cashen,Lukas D. Wartman,Matthew J. Walter,Peter Westervelt,Daniel C. Link,John F. DiPersio,Timothy J. Ley,John S. Welch
BLOOD WORK
-
Cover Image
Cover Image
Intravital 2-photon laser scanning microscopy image of the peritoneal membrane of a MacBlue×Cx3cr1gfp/+ transgenic mouse 4 hours after lipopolysaccharide treatment in the presence of CX3CR1 antagonist. Conjunctive tissue is visualized by second harmonic generation, blood vessels by rhodamine dextran, and circulating monocytes by enhanced cyan fluorescent protein expression. See the article by Hamon et al on page 1296.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals